* participation in another clinical trial of anti-viral agent(s) for covid-19 * receipt of any anti-viral agent(s) with possible activity against sars-cov-2 \<24 hours prior to study drug administration \[1\] * mechanically ventilated (including veno-venous (vv)-ecmo) ≥ 5 days * severe multi-organ failure * history of prior reactions to transfusion blood products meeting definitive case definition criteria, at least severe severity, and probable or definite imputability per national healthcare safety network (nhsn)/centers for disease control and prevention (cdc) criteria * known immunoglobulin a (iga) deficiency * females who are pregnant 1. use of remdesivir as treatment for covid-19 is permitted.

* participation in another clinical trial of anti-viral agent(s) for covid-19 * receipt of any anti-viral agent(s) with possible activity against sars-cov-2 \<24 hours prior to study drug administration \[1\] * mechanically ventilated (including veno-venous (vv)-ecmo) ≥ 5 days * severe multi-organ failure * history of prior reactions to transfusion blood products meeting definitive case definition criteria, at least severe severity, and probable or definite imputability per national healthcare safety network (nhsn)/centers for disease control and prevention (cdc) criteria * known immunoglobulin a (iga) deficiency * females who are pregnant 1. use of remdesivir as treatment for covid-19 is permitted.

participation in another clinical trial of anti-viral agent(s) for covid-19 receipt of any anti-viral agent(s) with possible activity against sars-cov-2 <24 hours prior to study drug administration [1] mechanically ventilated (including veno-venous (vv)-ecmo) ≥ 5 days severe multi-organ failure history of prior reactions to transfusion blood products meeting definitive case definition criteria, at least severe severity, and probable or definite imputability per national healthcare safety network (nhsn)/centers for disease control and prevention (cdc) criteria known immunoglobulin a (iga) deficiency females who are pregnant use of remdesivir as treatment for covid-19 is permitted.

participation in another clinical trial of anti-viral agent(s) for covid-19 receipt of any anti-viral agent(s) with possible activity against sars-cov-2 <24 hours prior to study drug administration [1] mechanically ventilated (including veno-venous (vv)-ecmo) ≥ 5 days severe multi-organ failure history of prior reactions to transfusion blood products meeting definitive case definition criteria, at least severe severity, and probable or definite imputability per national healthcare safety network (nhsn)/centers for disease control and prevention (cdc) criteria known immunoglobulin a (iga) deficiency females who are pregnant use of remdesivir as treatment for covid-19 is permitted.

- participation in another clinical trial of anti-viral agent(s) for covid-19 - receipt of any anti-viral agent(s) with possible activity against sars-cov-2 <24 hours prior to study drug administration [1] - mechanically ventilated (including veno-venous (vv)-ecmo) ≥ 5 days - severe multi-organ failure - history of prior reactions to transfusion blood products meeting definitive case definition criteria, at least severe severity, and probable or definite imputability per national healthcare safety network (nhsn)/centers for disease control and prevention (cdc) criteria - known immunoglobulin a (iga) deficiency - females who are pregnant 1. use of remdesivir as treatment for covid-19 is permitted.

- participation in another clinical trial of anti-viral agent(s) for covid-19 - receipt of any anti-viral agent(s) with possible activity against sars-cov-2 <24 hours prior to study drug administration [1] - mechanically ventilated (including veno-venous (vv)-ecmo) ≥ 5 days - severe multi-organ failure - history of prior reactions to transfusion blood products meeting definitive case definition criteria, at least severe severity, and probable or definite imputability per national healthcare safety network (nhsn)/centers for disease control and prevention (cdc) criteria - known immunoglobulin a (iga) deficiency - females who are pregnant 1. use of remdesivir as treatment for covid-19 is permitted.

- participation in another clinical trial of anti-viral agent(s) for covid-19 - receipt of any anti-viral agent(s) with possible activity against sars-cov-2 <24 hours prior to study drug administration - mechanically ventilated (including veno-venous (vv)-ecmo) ≥ 5 days - severe multi-organ failure - history of prior reactions to transfusion blood products meeting definitive case definition criteria, at least severe severity, and probable or definite imputability per national healthcare safety network (nhsn)/centers for disease control and prevention (cdc) criteria - known immunoglobulin a (iga) deficiency - females who are pregnant

- participation in another clinical trial of anti-viral agent(s) for covid-19 - receipt of any anti-viral agent(s) with possible activity against sars-cov-2 <24 hours prior to study drug administration - mechanically ventilated (including veno-venous (vv)-ecmo) ≥ 5 days - severe multi-organ failure - history of prior reactions to transfusion blood products meeting definitive case definition criteria, at least severe severity, and probable or definite imputability per national healthcare safety network (nhsn)/centers for disease control and prevention (cdc) criteria - known immunoglobulin a (iga) deficiency - females who are pregnant